COVID-19 Booster Vaccine for Immunocompromised Individuals
What You Need to Know Before You Apply
What is the purpose of this trial?
To determine whether providing a recombinant booster COVID-19 vaccine improves sustained humoral and cell-mediated immunogenicity against SARS-CoV-2 in immunosuppressed patients with Inflammatory Bowel Disease (IBD) and/or solid organ transplant recipients. 120 participants will be enrolled and can expect to be on study for 6 months.
Who Is on the Research Team?
Freddy Caldera, DO, MS
Principal Investigator
UW School of Medicine and Public Health
Are You a Good Fit for This Trial?
This trial is for people with Inflammatory Bowel Disease or those who've had an organ transplant and have already received a COVID-19 vaccine. They should be on specific treatments for their condition but can't join if they've had recent organ rejection, allergies to the vaccine, are pregnant/breastfeeding, recently used steroids for IBD flare-ups, or currently have COVID-19.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline
Baseline visit where blood samples are collected before the booster dose
Treatment
Participants receive a recombinant COVID-19 vaccine booster dose
Follow-up
Participants are monitored for safety and effectiveness after treatment, with blood samples collected at 1 month and 6 months post-booster
What Are the Treatments Tested in This Trial?
Interventions
- NVX-CoV2372
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Wisconsin, Madison
Lead Sponsor
Novavax
Industry Sponsor